AMG-517
Modify Date: 2025-08-21 14:41:38
AMG-517 structure
|
Common Name | AMG-517 | ||
|---|---|---|---|---|
| CAS Number | 659730-32-2 | Molecular Weight | 430.403 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C20H13F3N4O2S | Melting Point | 227ºC | |
| MSDS | N/A | Flash Point | N/A | |
Use of AMG-517AMG 517 is a potent and selective vanilloid receptor-1 (TRPV1) antagonist with an IC50 of 0.5 nM. |
| Name | N-[4-[6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide |
|---|---|
| Synonym | More Synonyms |
| Description | AMG 517 is a potent and selective vanilloid receptor-1 (TRPV1) antagonist with an IC50 of 0.5 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.5 nM (TRPV1)[1] |
| In Vitro | AMG 517 retains potency in the capsaicin- and acid-mediated assays with IC50 values of 0.9 and 0.5 nM[1]. AMG 517 inhibits capsaicin, pH 5, and heat-induced45Ca2+ uptake into cells expressing TRPV1 with IC50 values of 1 to 2 nM. AMG 517 blocks capsaicin-, proton-, and heat-induced inward currents in TRPV1-expressing cells similarly. AMG 517 inhibits native TRPV1 activation by capsaicin in rat dorsal root ganglion neurons with an IC50 value of 0.68 ± 0.2 nM. AMG 517 is a competitive antagonist of both rat and human TRPV1 with dissociation constant (Kb) values of 4.2 and 6.2 nM, respectively[2]. |
| In Vivo | AMG 517 is shown to be effective in a rodent “on-target” biochemical challenge model (capsaicin-induced flinch, ED50=0.33 mg/kg p.o.) and is antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED=0.83 mg/kg, p.o.)[1].The minimally effective dose is 0.3 mg/kg for AMG 517 and the corresponding plasma concentration is 90 ng/mL. Oral administration of AMG 517 reverses established thermal hyperalgesia in a dose-dependent manner at 21 h after CFA injection. AMG 517 causes transient hyperthermia in rodents, dogs, and monkeys. AMG 517 induces hyperthermia in a steep dose-dependent manner, with 0.3, 1, and 3 mg/kg associated with 0.5, 0.6, and 1.6°C increases in body temperature, respectively. Body temperatures of rats treated with all doses of AMG 517 return to baseline within 10 to 20 h[2]. |
| Animal Admin | Rats: After multiple days of full habituation to the testing equipment and paradigm, CFA-induced thermal hyperalgesia is evaluated by measuring paw withdrawal latencies in male Sprague-Dawley rats. Twenty-one hours after CFA injection (50 μL of 0.1%), animals are dosed (p.o.) with AMG 517 or AMG8163 at a dose range of 0.001 to 30 mg/kg in a volume of 5 mL/kg. Two hours after drug dosing (23 h after CFA injection), paw withdrawal latencies are measured using modified Hargreaves hot boxes by investigators fully blinded to treatment conditions[2]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Melting Point | 227ºC |
| Molecular Formula | C20H13F3N4O2S |
| Molecular Weight | 430.403 |
| Exact Mass | 430.071136 |
| PSA | 108.73000 |
| LogP | 5.41 |
| Index of Refraction | 1.645 |
| Storage condition | -20℃ |
|
~48%
AMG-517 CAS#:659730-32-2 |
| Literature: Doherty, Elizabeth M.; Fotsch, Christopher; Bannon, Anthony W.; Bo, Yunxin; Chen, Ning; Dominguez, Celia; Falsey, James; Gavva, Narender R.; Katon, Jodie; Nixey, Thomas; Ognyanov, Vassil I.; Pettus, Liping; Rzasa, Robert M.; Stec, Markian; Surapaneni, Sekhar; Tamir, Rami; Zhu, Jiawang; Treanor, James J. S.; Norman, Mark H. Journal of Medicinal Chemistry, 2007 , vol. 50, # 15 p. 3515 - 3527 |
|
~%
AMG-517 CAS#:659730-32-2 |
| Literature: Journal of Medicinal Chemistry, , vol. 50, # 15 p. 3515 - 3527 |
|
~%
AMG-517 CAS#:659730-32-2 |
| Literature: Journal of Medicinal Chemistry, , vol. 50, # 15 p. 3515 - 3527 |
![4-[6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy]benzothiazol-2-ylamine structure](https://image.chemsrc.com/caspic/417/659730-31-1.png)
| BD-0082 |
| N-(4-(6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide |
| UNII-172V4FBZ75 |
| N-[4-({6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl}oxy)-1,3-benzothiazol-2-yl]acetamide |
| Acetamide, N-[4-[[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]- |
| N-[4-({6-[4-(Trifluoromethyl)phenyl]-4-pyrimidinyl}oxy)-1,3-benzothiazol-2-yl]acetamide |
| N-[4-[[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-acetamide |
| AMG-517 |
| N-(4-(6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy)benzothiazol-2-yl)acetamide |
| N-(4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl)-acetamide |
| AMG517 |
| AMG 517 |